MedTrace Logo

Study to Evaluate the Safety and PK of UI018

NCT05085184 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-12-21

No results posted yet for this study

Summary

This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.

Conditions

  • Hyperlipemia, Mixed

Interventions

DRUG

administration of UI018

Test

DRUG

co-administration of UIC201806 and UIC201602

Reference

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Principal Investigators

  • Injin Jang, Dr. · Seoul National University College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2021-11-30
Completion
2022-09-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05085184 on ClinicalTrials.gov